Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 12:30:11 2026-03-13 pm EDT			5-day change	1st Jan Change
121.36 ^CHF	+0.43%		-1.54%	+10.73%

02:06am	Novartis board of directors has decided to launch a new share buyback program	RE
01:55am	Swiss stocks - Factors to watch on March 16	RE

Novartis AG Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025

Published on 02/04/2026 at 09:07 am EST - Modified on 02/04/2026 at 02:52 pm EST

S&P Capital IQ

NOVARTIS AG

+0.43%

Novartis AG reported earnings results for the fourth quarter and full year ended December 31, 2025. For the fourth quarter, the company reported sales was USD 13,336 million compared to USD 13,153 million a year ago. Net income was USD 2,409 million compared to USD 2,818 million a year ago. Basic earnings per share from continuing operations was USD 1.26 compared to USD 1.42 a year ago. Diluted earnings per share from continuing operations was USD 1.25 compared to USD 1.41 a year ago.
For the full year, sales was USD 54,532 million compared to USD 50,317 million a year ago. Net income was USD 13,984 million compared to USD 11,941 million a year ago. Basic earnings per share from continuing operations was USD 7.21 compared to USD 5.92 a year ago. Diluted earnings per share from continuing operations was USD 7.15 compared to USD 5.87 a year ago. Basic earnings per share was USD 7.21 compared to USD 5.92 a year ago. Diluted earnings per share was USD 7.15 compared to USD 5.87 a year ago.

Latest news about Novartis AG

02:06am	Novartis board of directors has decided to launch a new share buyback program	RE
01:55am	Swiss stocks - Factors to watch on March 16	RE
12:16am	Novartis Wins US FDA Nod for Hidradenitis Suppurativa Treatment for Patients Over 12 Years Old	MT
Mar. 13	Novartis Announces FDA Approval for Cosentyx for Pediatric Patients with Moderate to Severe Hidradenitis Suppurativa	CI
Mar. 13	Novartis Gets FDA Approval for Cosentyx in Pediatric Patients	MT
Mar. 13	Novartis Cosentyx(R) receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa	DJ
Mar. 12	Viatris settles lawsuit over use of woman's 'immortal' cells to power drug research	RE
Mar. 12	Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs	CI
Mar. 12	Ipsen Announces Executive Changes	CI
Mar. 10	Swiss stocks - Factors to watch on March 10	RE
Mar. 09	Global drugmakers rush to boost US presence as tariff threat looms	RE
Mar. 09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update	DJ
Mar. 09	Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study	DJ
Mar. 09	UBS keeps CEO's pay steady at $19 million as regulatory changes loom	RE
Mar. 09	Berenberg Notes Novartis 'Fully Valued' After FY25 Report Review; Price Target Up	MT

Chart Novartis AG

Duration

Period

NOVN: Dynamic Chart

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Apr. 28 - Earnings release - Q1 2026

More about the company